Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of black cumin seed oil and astaxanthin is a nutraceutical formulation developed by TriNutra. It typically combines 500 mg of black cumin seed oil (standardized to 3% thymoquinone, branded as ThymoQuin) with 8 mg of microalgae-derived astaxanthin oleoresin (branded as AstaPure). This formulation acts as an immune modulator targeting the gut-immune-brain axis through anti-inflammatory and antioxidant mechanisms. Clinical studies have evaluated this combination for its ability to support immune health, reduce the incidence of upper respiratory tract complaints, and improve psychological mood states, particularly in individuals experiencing physical and mental stress such as endurance athletes. The product is typically delivered in a softgel dosage form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on black cumin seed oil + astaxanthin.